Artisan Partners Limited Partnership Takes $7.40 Million Position in Replimune Group, Inc. (NASDAQ:REPL)

Artisan Partners Limited Partnership acquired a new stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 611,013 shares of the company's stock, valued at approximately $7,399,000. Artisan Partners Limited Partnership owned 0.89% of Replimune Group at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Braidwell LP increased its holdings in shares of Replimune Group by 203.0% in the third quarter. Braidwell LP now owns 3,070,837 shares of the company's stock worth $33,656,000 after purchasing an additional 2,057,460 shares during the period. State Street Corp increased its position in shares of Replimune Group by 102.1% in the third quarter. State Street Corp now owns 2,340,042 shares of the company's stock worth $25,647,000 after purchasing an additional 1,182,181 shares during the last quarter. Baker BROS. Advisors LP raised its stake in Replimune Group by 10.0% in the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company's stock valued at $121,057,000 after purchasing an additional 1,000,000 shares in the last quarter. Rosalind Advisors Inc. bought a new stake in Replimune Group during the fourth quarter valued at approximately $3,149,000. Finally, Parkman Healthcare Partners LLC grew its stake in Replimune Group by 45.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company's stock worth $8,371,000 after buying an additional 238,747 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently commented on the company. BMO Capital Markets increased their target price on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. Jefferies Financial Group increased their price objective on Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday, December 4th. JPMorgan Chase & Co. boosted their target price on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Finally, HC Wainwright upped their target price on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $19.43.

Replimune Group Stock Performance

Shares of Replimune Group stock traded up $0.66 during trading hours on Wednesday, reaching $9.06. 476,671 shares of the stock traded hands, compared to its average volume of 728,411. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $17.00. The firm has a market capitalization of $697.76 million, a price-to-earnings ratio of -2.95 and a beta of 1.30. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. The company has a 50 day moving average price of $12.60 and a 200 day moving average price of $12.14.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, equities research analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.